

**Supplementary Table 1. Baseline characteristics of the drop-outs.**

	M-group (n=34)	S-group (n=28)	Control group (n=44)
Sex (% male)	38.2	67.9	47.7
Age (years)	56±12	61±9	62±7 <sup>†</sup>
Weight (kg)	112±19	113±23	106±20
BMI (kg/m <sup>2</sup> )	37.9±5.8	38.0±7.9	36.6±5.4
HbA <sub>1c</sub> (%)	8.7±1.7	8.5±1.6	8.1±1.1
Known diabetes duration (years)	8±6	11±10	13±6 <sup>†</sup>
FBG (mg/dl)	182±59	182±61	176±55
SBP (mmHg)	134±13	139±16	134±14
DBP (mmHg)	81±8	82±5	78±8
Total cholesterol (mg/dl)	207±43	207±36	190±42
HDL (mg/dl)	47±12	47±11	50±24
LDL (mg/dl)	130±33	120±31	113±33
Triglyceride (mg/dl)	406±604	243±182	216±84
TFEQ [cognitive control] (au)	10 (8; 12)	9 (6; 11)	7 (6; 8) <sup>‡, §§</sup>
TFEQ [suggestibility] (au)	7 (5; 10)	7 (4; 10)	5 (3; 6) <sup>‡</sup>
TFEQ [hunger] (au)	7 (5; 8)	7 (4; 11)	5 (4; 6)
SF36 [physical health] (au)	41 (30; 48)	39 (30; 45)	37 (30; 47)
SF36 [mental health] (au)	49 (35; 56)	48 (33; 57)	38 (35; 42) <sup>‡, §§</sup>

Shown are means ± standard deviations, median (1st; 3rd quartiles) or percentages. <sup>‡</sup> CON vs. M-group, p<0.01; <sup>†</sup> CON vs. M-group, p<0.05; <sup>§§</sup> CON vs. S-group, p<0.01; Underlined symbols (‡, †) represent significant differences after Bonferroni correction for multiple testing; au, arbitrary units; FBG, fasting blood glucose; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density-lipoprotein; LDL, low-density-lipoprotein; SBP, systolic blood pressure; SF36, short form-36; TFEQ, three-factor eating questionnaire

**Supplementary Table 2. Baseline antidiabetic drugs.**

	M-group (n=125)	S-group (n=122)	Control group (n=74)	P (M- vs. S- group)	P (M- vs. Control- group)	P (S- vs. Control- group)
No medication (%)	8.0	8.2	0	1.000		0.014
Metformin (%)	81.6	77.0	89.2	0.433	0.164	0.037
DPP4 inhibitors (%)	28.8	24.6	33.8	0.475	0.525	0.111
Sulfonylureas (%)	6.4	4.1	13.5	0.571	0.124	0.018
Glinides (%)	0	0	5.4	1.000	0.018	0.019
Glitazone (%)	2.0	0.8	1.4	1.000	1.000	1.000
Glucosidase inhibitors (%)	0	0.8	0	0.494	1.000	1.000
GLP-1 receptor agonists (%)	12.0	8.2	21.6	0.400	0.104	0.009
Sodium-glucose co- transporter-2 (%)	0.8	0.8	4.2	0.742	0.402	0.405
Insulin (%)	19.2	19.7	75.7 <sup>a,b</sup>	1.000	<0.001	<0.001

Data are shown as percentages. Superscript letters a (M-group vs. control group) and b (S-group vs. control group) represent significant differences after Bonferroni correction for multiple testing; DDP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1.